Haemovigilance data on the use of methylene blue virally inactivated fresh frozen plasma with the Theraflex MB-Plasma System in comparison to quarantine plasma: 11 years' experience

Transfusion Medicine

Volumn 24, Issue 5, 2014, Pages 316-320

  Politis, C ^a   Kavallierou, L ^b   Hantziara, S ^c   Parara, M ^d   Zervou, E ^e   Katsarou, O ^f   Hatzitaki, M ^g   Fountouli, P ^h   Gioka, A ⁱ   Tzioura, K ^j   Koumarianos, S ^a   Asariotou, M ^a   Richardson, C ^k  

^a Hellenic Centre for Disease Control and Prevention   (Greece)

^b AMALIA FLEMING GENERAL HOSPITAL   (Greece)

^c G GENNIMATAS GENERAL HOSPITAL   (Greece)

^d EVANGELISMOS HOSPITAL   (Greece)

^e UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^f LAIKO GENERAL HOSPITAL   (Greece)

^g Koutlimpanio General Hospital   (Greece)

^h UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

ⁱ G HATZIKOSTA GENERAL HOSPITAL   (Greece)

^j General District Hospital of Serres   (Greece)

^k PANTEION UNIVERSITY   (Greece)

more..

Author keywords

blood quality; haemovigilance; pathogen inactivation

Indexed keywords

BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; FRESH FROZEN PLASMA; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 6; INTERLEUKIN 8; METHYLENE BLUE;

ALLERGIC REACTION; ARTICLE; BLOOD COMPONENT; BLOOD SAFETY; BLOOD TRANSFUSION; CONTROLLED STUDY; DISEASE SEVERITY; GREECE; HUMAN; INCIDENCE; LONG TERM CARE; PLASMA EXCHANGE; PLASMA TRANSFUSION; QUARANTINE; SEPTIC SHOCK; SEPTICEMIA; STAPHYLOCOCCUS INFECTION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSFUSION RELATED ACUTE LUNG INJURY;

EID: 85007158390     PISSN: 09587578     EISSN: 13653148     Source Type: Journal    
DOI: 10.1111/tme.12144     Document Type: Article

References (15)

1. Bolton-Maggs, P.H.B. (2013) Transfusion safety in 2012: main messages from the SHOT Annual Report for 2012. Transfusion Medicine, 23, 217–218.
2. Bost, V., Odent-Malaure, H., Chavarin, P., Benamara, H., Fabrigli, P. & Garraud, O. (2013) A regional haemovigilance retrospective study of four types of therapeutic plasma in a ten-year survey period in France. Vox Sanguinis, 104, 337–341.
3. Council of Europe (2013) Guide to the Preparation, Use and Quality Assurance of Blood Components, Recommendation No. R(95)15 (17th edn). EDQM, Strasbourg.
4. European Commission (2003). Directive 2002/98/EC of the European Parliament and of the Council of 27 January 2003 setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components and amending Directive 2001/83/EC. 2002/98/EC.
5. European Commission (2005). Commission Directive 2005/61/EC of 30 September 2005 implementing Directive 2002/98/EC of the European Parliament and of the Council as regards traceability requirements and notification of serious adverse reactions and events. 2005/61/EC.
6. Hellenic Coordinating Haemovigilance Centre (SKAE) (2012). Epidemiological surveillance of transfusion transmitted infections (1996-2011), surveillance of adverse reactions and adverse events associated with blood transfusion (1997-2011), surveillance of adverse reactions and adverse events during or after donation (2003-2011). Summary Report. (In Greek). Hellenic Centre for Disease Control and Prevention, Athens [WWW document]. URL http://www.keelpno.gr (Accessed 6/12/13).
7. Mertes, P.M., Demoly, P., Alperovitch, A. et al. (2012) Methylene blue-treated plasma: an increased allergy risk? Journal of Allergy and Clinical Immunology, 130, 808–812.
8. Mohr, H., Knuver-Hopf, J., Gravemann, U., Redecker-Klein, A. & Muller, T.H. (2004) West Nile virus in plasma is highly sensitive to methylene blue-light treatment. Transfusion, 44, 886–890.
9. New, H., Tinegate, H., Hunt, I., Bolton-Maggs, P. & Cardigan, R. (2012) Methylene blue-treated plasma. Joint UKBTS/HPA Professional Advisory Committee/Serious Hazards of Transfusion (SHOT) Position statement [WWW document]. URL http://www.transfusionguidelines.org.uk/Index.asp?Publications=DL&Section=12&pageid=7737 (Accessed 1/12/13).
10. Politis, C. (2012) Establishment of haemovigilance for the testing, storage, distribution, transport and issuing of blood and blood components: the example of Greece. In: Hemovigilance: An Effective Tool for Improving Transfusion Safety (eds De Vries, R.R.P. & Faber, J.-C.), 52–60. John Wiley, Chichester.
11. Politis, C., Kavallierou, L., Hantziara, S. et al. (2007) Quality and safety of fresh-frozen plasma inactivated and leucoreduced with the Theraflex methylene blue system including the Blueflex filter: 5 years' experience. Vox Sanguinis, 92, 319–326.
12. Politis, C., Asariotou, M., Koumarianos, S., Richardson, C., Damaskos, P. & Botsi, C. (2009) Look back programme for HIV seropositive donors in Hellas. Vox Sanguinis, 96 (Suppl. 1), 142–143.
13. Politis, C., Grazzini, G., Sandid, I., Pouchol, E., Posea, C. & Dobrota, M.A. (2012) West Nile virus and blood safety: Introduction to a preparedness plan in Europe. (v.2.1). Working Group on Blood Safety and WNV [WWW document]. URL http://ec.europa.eu/health/blood_tissues_organs/docs/wnv_preparedness_plan_2012.pdf (Accessed 1/12/13).
14. Seghatchian, J., Struff, W.G. & Reichenberg, S. (2011) Main properties of the Theraflex MB-Plasma System for pathogen reduction. Transfusion Medicine and Hemotherapy, 38, 55–64.
15. de, Vries, R.R.P., Faber, J.-C. & Strengers, P.F.W. (2011) Haemovigilance: an effective tool for improving transfusion practice. Vox Sanguinis, 100, 60–67.